vs

Side-by-side financial comparison of Array Technologies, Inc. (ARRY) and Axsome Therapeutics, Inc. (AXSM). Click either name above to swap in a different company.

Array Technologies, Inc. is the larger business by last-quarter revenue ($226.0M vs $196.0M, roughly 1.2× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs -17.9%). Array Technologies, Inc. produced more free cash flow last quarter ($36.2M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 21.4%).

ATI Technologies Inc. was a Canadian semiconductor technology corporation based in Markham, Ontario, that specialized in the development of graphics processing units and chipsets. Founded in 1985, the company listed publicly in 1993 and was acquired by AMD in 2006. As a major fabless semiconductor company, ATI conducted research and development in-house and outsourced the manufacturing and assembly of its products. With the decline and eventual bankruptcy of 3dfx in 2000, ATI and its chief ri...

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

ARRY vs AXSM — Head-to-Head

Bigger by revenue
ARRY
ARRY
1.2× larger
ARRY
$226.0M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+82.9% gap
AXSM
65.0%
-17.9%
ARRY
More free cash flow
ARRY
ARRY
$54.9M more FCF
ARRY
$36.2M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
21.4%
ARRY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARRY
ARRY
AXSM
AXSM
Revenue
$226.0M
$196.0M
Net Profit
$-28.6M
Gross Margin
8.6%
Operating Margin
-65.5%
-13.8%
Net Margin
-14.6%
Revenue YoY
-17.9%
65.0%
Net Profit YoY
61.9%
EPS (diluted)
$-1.06
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARRY
ARRY
AXSM
AXSM
Q4 25
$226.0M
$196.0M
Q3 25
$393.5M
$171.0M
Q2 25
$362.2M
$150.0M
Q1 25
$302.4M
$121.5M
Q4 24
$275.2M
$118.8M
Q3 24
$231.4M
$104.8M
Q2 24
$255.8M
$87.2M
Q1 24
$153.4M
$75.0M
Net Profit
ARRY
ARRY
AXSM
AXSM
Q4 25
$-28.6M
Q3 25
$33.5M
$-47.2M
Q2 25
$43.3M
$-48.0M
Q1 25
$16.7M
$-59.4M
Q4 24
$-74.9M
Q3 24
$-141.4M
$-64.6M
Q2 24
$25.7M
$-79.3M
Q1 24
$2.2M
$-68.4M
Gross Margin
ARRY
ARRY
AXSM
AXSM
Q4 25
8.6%
Q3 25
26.9%
Q2 25
26.8%
Q1 25
25.3%
Q4 24
28.5%
Q3 24
33.8%
Q2 24
33.6%
Q1 24
35.9%
Operating Margin
ARRY
ARRY
AXSM
AXSM
Q4 25
-65.5%
-13.8%
Q3 25
11.6%
-27.0%
Q2 25
12.8%
-24.5%
Q1 25
9.0%
-46.9%
Q4 24
-51.7%
-61.1%
Q3 24
-57.3%
-59.8%
Q2 24
15.5%
-89.5%
Q1 24
5.5%
-89.7%
Net Margin
ARRY
ARRY
AXSM
AXSM
Q4 25
-14.6%
Q3 25
8.5%
-27.6%
Q2 25
11.9%
-32.0%
Q1 25
5.5%
-48.9%
Q4 24
-63.1%
Q3 24
-61.1%
-61.7%
Q2 24
10.0%
-91.0%
Q1 24
1.4%
-91.1%
EPS (diluted)
ARRY
ARRY
AXSM
AXSM
Q4 25
$-1.06
$-0.55
Q3 25
$0.12
$-0.94
Q2 25
$0.19
$-0.97
Q1 25
$0.02
$-1.22
Q4 24
$-0.94
$-1.54
Q3 24
$-1.02
$-1.34
Q2 24
$0.08
$-1.67
Q1 24
$-0.07
$-1.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARRY
ARRY
AXSM
AXSM
Cash + ST InvestmentsLiquidity on hand
$244.4M
$322.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-206.3M
$88.3M
Total Assets
$1.5B
$689.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARRY
ARRY
AXSM
AXSM
Q4 25
$244.4M
$322.9M
Q3 25
$221.5M
$325.3M
Q2 25
$377.3M
$303.0M
Q1 25
$348.3M
$300.9M
Q4 24
$363.0M
$315.4M
Q3 24
$332.4M
$327.3M
Q2 24
$282.3M
$315.7M
Q1 24
$287.6M
$331.4M
Stockholders' Equity
ARRY
ARRY
AXSM
AXSM
Q4 25
$-206.3M
$88.3M
Q3 25
$-46.7M
$73.7M
Q2 25
$-70.9M
$73.1M
Q1 25
$-97.8M
$53.2M
Q4 24
$-118.1M
$57.0M
Q3 24
$64.5M
$92.9M
Q2 24
$200.0M
$102.9M
Q1 24
$231.2M
$144.0M
Total Assets
ARRY
ARRY
AXSM
AXSM
Q4 25
$1.5B
$689.8M
Q3 25
$1.6B
$669.3M
Q2 25
$1.5B
$639.8M
Q1 25
$1.4B
$596.7M
Q4 24
$1.4B
$568.5M
Q3 24
$1.6B
$561.5M
Q2 24
$1.7B
$548.2M
Q1 24
$1.6B
$545.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARRY
ARRY
AXSM
AXSM
Operating Cash FlowLast quarter
$43.6M
$-18.7M
Free Cash FlowOCF − Capex
$36.2M
$-18.7M
FCF MarginFCF / Revenue
16.0%
-9.6%
Capex IntensityCapex / Revenue
3.3%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$79.8M
$-93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARRY
ARRY
AXSM
AXSM
Q4 25
$43.6M
$-18.7M
Q3 25
$27.4M
$1.0M
Q2 25
$43.8M
$-32.4M
Q1 25
$-13.1M
$-43.4M
Q4 24
$57.6M
$-26.2M
Q3 24
$44.9M
$-18.6M
Q2 24
$4.0M
$-30.1M
Q1 24
$47.5M
$-53.5M
Free Cash Flow
ARRY
ARRY
AXSM
AXSM
Q4 25
$36.2M
$-18.7M
Q3 25
$21.9M
$988.0K
Q2 25
$37.2M
$-32.4M
Q1 25
$-15.4M
$-43.7M
Q4 24
$55.9M
$-26.2M
Q3 24
$43.9M
$-18.7M
Q2 24
$1.8M
$-30.2M
Q1 24
$45.1M
$-53.6M
FCF Margin
ARRY
ARRY
AXSM
AXSM
Q4 25
16.0%
-9.6%
Q3 25
5.6%
0.6%
Q2 25
10.3%
-21.6%
Q1 25
-5.1%
-36.0%
Q4 24
20.3%
-22.1%
Q3 24
19.0%
-17.9%
Q2 24
0.7%
-34.6%
Q1 24
29.4%
-71.4%
Capex Intensity
ARRY
ARRY
AXSM
AXSM
Q4 25
3.3%
0.0%
Q3 25
1.4%
0.0%
Q2 25
1.8%
0.0%
Q1 25
0.8%
0.3%
Q4 24
0.6%
0.0%
Q3 24
0.5%
0.1%
Q2 24
0.8%
0.1%
Q1 24
1.6%
0.1%
Cash Conversion
ARRY
ARRY
AXSM
AXSM
Q4 25
Q3 25
0.82×
Q2 25
1.01×
Q1 25
-0.78×
Q4 24
Q3 24
Q2 24
0.15×
Q1 24
21.94×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARRY
ARRY

Array Legacy Operations Segment$212.0M94%
STI Operations Segment$14.0M6%

AXSM
AXSM

Segment breakdown not available.

Related Comparisons